文献
J-GLOBAL ID:201802284341686336
整理番号:18A0606538
Lucerastat,基質減少療法のためのイミノ糖:忍容性,薬力学,および酵素置換のFabry病患者における薬物動力学【Powered by NICT】
Lucerastat, an Iminosugar for Substrate Reduction Therapy: Tolerability, Pharmacodynamics, and Pharmacokinetics in Patients With Fabry Disease on Enzyme Replacement
著者 (8件):
Guerard Nicolas
(Department of Global Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland)
,
Oder Daniel
(Fabry Center for Interdisciplinary Therapy (FAZiT), Comprehensive Heart Failure Center (CHFC), and Department of Internal Medicine I, Divisions of Cardiology and Nephrology, University Hospital Wuerzburg, Wuerzburg, Germany)
,
Nordbeck Peter
(Fabry Center for Interdisciplinary Therapy (FAZiT), Comprehensive Heart Failure Center (CHFC), and Department of Internal Medicine I, Divisions of Cardiology and Nephrology, University Hospital Wuerzburg, Wuerzburg, Germany)
,
Zwingelstein Christian
(Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland)
,
Morand Olivier
(Department of Global Clinical Science, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland)
,
Welford Richard W.D.
(DD Biology, Translational Science, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland)
,
Dingemanse Jasper
(Department of Global Clinical Pharmacology, Idorsia Pharmaceuticals Ltd, Allschwil, Switzerland)
,
Wanner Christoph
(Fabry Center for Interdisciplinary Therapy (FAZiT), Comprehensive Heart Failure Center (CHFC), and Department of Internal Medicine I, Divisions of Cardiology and Nephrology, University Hospital Wuerzburg, Wuerzburg, Germany)
資料名:
Clinical Pharmacology & Therapeutics
(Clinical Pharmacology & Therapeutics)
巻:
103
号:
4
ページ:
703-711
発行年:
2018年
JST資料番号:
A0721B
ISSN:
0009-9236
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)